Ligand Pharmaceuticals INC (LGND) Shareholder Cardinal Capital Management LLC Has Lowered Its Position by $35.48 Million

July 16, 2018 - By Catherine Diaz

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) LogoInvestors sentiment decreased to 1.06 in 2018 Q1. Its down 0.19, from 1.25 in 2017Q4. It turned negative, as 16 investors sold LGND shares while 109 reduced holdings. 52 funds opened positions while 80 raised stakes. 22.56 million shares or 0.54% less from 22.68 million shares in 2017Q4 were reported. Kopp Inv Advsrs invested in 21,405 shares. 13,104 were reported by Intll Grp Inc. Great West Life Assurance Can holds 0.01% or 28,062 shares. Moreover, Gabelli Funds Ltd Llc has 0.03% invested in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) for 27,575 shares. Texas Permanent School Fund invested in 13,971 shares or 0.03% of the stock. Royal Savings Bank Of Canada accumulated 0.01% or 101,430 shares. 19,539 were reported by Court Place Ltd. Bessemer has invested 0% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Aperio Group Inc Ltd Liability Co reported 24,421 shares or 0.02% of all its holdings. Eam Invsts Limited Liability holds 21,017 shares or 0.58% of its portfolio. California State Teachers Retirement holds 0.01% or 31,219 shares. Nuveen Asset Management Ltd Liability reported 0.01% of its portfolio in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Retail Bank Of America Corp De has 318,502 shares for 0.01% of their portfolio. Oak Ridge Invs Lc holds 247,182 shares. Comerica National Bank reported 33,151 shares.

Since January 19, 2018, it had 0 buys, and 14 selling transactions for $20.81 million activity. KOZARICH JOHN W had sold 2,500 shares worth $401,063. Aryeh Jason sold 7,500 shares worth $1.32 million. 8,881 shares valued at $1.49 million were sold by FOEHR MATTHEW W on Thursday, May 10. Shares for $778,039 were sold by LAMATTINA JOHN L on Monday, June 4. Shares for $2.62 million were sold by Davis Todd C. Sabba Stephen L also sold $112,414 worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) shares.

Cardinal Capital Management Llc decreased its stake in Ligand Pharmaceuticals Inc (LGND) by 32.86% based on its latest 2018Q1 regulatory filing with the SEC. Cardinal Capital Management Llc sold 215,011 shares as the company’s stock rose 24.00% while stock markets declined. The institutional investor held 439,335 shares of the major pharmaceuticals company at the end of 2018Q1, valued at $72.56 million, down from 654,346 at the end of the previous reported quarter. Cardinal Capital Management Llc who had been investing in Ligand Pharmaceuticals Inc for a number of months, seems to be less bullish one the $4.71 billion market cap company. The stock decreased 0.08% or $0.18 during the last trading session, reaching $220.91. About 127,978 shares traded. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has risen 66.74% since July 16, 2017 and is uptrending. It has outperformed by 54.17% the S&P500.

Cardinal Capital Management Llc, which manages about $1.96B and $2.69B US Long portfolio, upped its stake in Silicon Motion Technology Co (NASDAQ:SIMO) by 209,757 shares to 1.47M shares, valued at $70.66M in 2018Q1, according to the filing. It also increased its holding in Kar Auction Svcs Inc (NYSE:KAR) by 269,763 shares in the quarter, for a total of 1.91M shares, and has risen its stake in Callon Pete Co Del (NYSE:CPE).

Analysts await Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) to report earnings on August, 6. They expect $0.78 earnings per share, up 44.44 % or $0.24 from last year’s $0.54 per share. LGND’s profit will be $16.63 million for 70.80 P/E if the $0.78 EPS becomes a reality. After $1.38 actual earnings per share reported by Ligand Pharmaceuticals Incorporated for the previous quarter, Wall Street now forecasts -43.48 % negative EPS growth.

More notable recent Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) news were published by: Prnewswire.com which released: “Rev. Fr. Emmanuel Lemelson Calls on Congress, Office of Inspector General to Investigate SEC Failures” on July 13, 2018, also Streetinsider.com with their article: “Ligand Pharma (LGND) Updates 2018 Revenue Guidance; Secures $47M Payment from WuXi Biologics for Expansion …” published on June 27, 2018, Fool.com published: “3 Top Biotech Stocks to Buy Right Now” on July 13, 2018. More interesting news about Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) were released by: Seekingalpha.com and their article: “Ligand Pharma teams up with J&J to develop transgenic chicken platform” published on July 11, 2018 as well as Nasdaq.com‘s news article titled: “Analysis: Positioning to Benefit within EMCOR Group, Ring Energy, AO Smith, bluebird bio, Ligand Pharmaceuticals …” with publication date: June 28, 2018.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Ratings Coverage

Among 5 analysts covering Ligand Pharmaceuticals (NASDAQ:LGND), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Ligand Pharmaceuticals had 8 analyst reports since January 24, 2018 according to SRatingsIntel. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, January 24. The firm earned “Buy” rating on Monday, February 26 by Roth Capital. Craig Hallum maintained the stock with “Buy” rating in Wednesday, June 27 report. The stock has “Buy” rating by H.C. Wainwright on Wednesday, March 7. The rating was maintained by Craig Hallum on Wednesday, March 7 with “Buy”. As per Thursday, February 22, the company rating was maintained by Stephens. On Thursday, February 22 the stock rating was maintained by Craig Hallum with “Buy”.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.